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Although patients with hormone receptor (HR)epositive breast cancer are successfully treated with
endocrine therapy, many tumors go on to develop resistance to these agents. Studies have determined
that mechanisms of resistance to endocrine therapy are quite complex and can involve a multitude of
signal transduction pathways, either through direct association with the estrogen receptor or through
cross-talk with other pathways. Preclinical studies have suggested the therapeutic importance of the
mammalian target of rapamycin (mTOR) pathway and that inhibiting this pathway may restore sensi-
tivity to endocrine therapy. The oral mTOR inhibitor everolimus has been extensively studied for breast
cancer. Clinical studies suggest that everolimus in combination with endocrine therapy improves
progression-free survival and is well tolerated. A combined approach, targeting both mTOR signal
transduction and the HR pathways, promises to take clinical research in a new direction for the treat-
ment of HR-positive advanced breast cancer.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Overview of breast cancer
Breast cancer is the most common malignancy in women. It is
estimated that approximately 226,870 women will be diagnosed
with and 39,510 women will die of breast cancer in the United
States in 2012.1 The most common histologic type of breast cancer
is ductal carcinoma; lobular carcinoma, Paget’s disease, and sar-
coma are less common.1 Classiﬁcation of breast cancer may also
involve estrogen receptor (ER)/progesterone receptor (PR) status,
human epidermal growth factor receptor-2 (HER2)/neu ampliﬁca-
tion status, grade, and stage of the disease.2e4
Endocrine therapy
Estrogen hormones play a major role in the development and
progression of hormone receptor (HR)epositive breast cancer. The
majority of breast tumors express ER and/or PR, and endocrine
therapy has proven beneﬁcial in all stages of the disease.5,6 Multiple
treatment strategies have been developed for the treatment of HR-
positive breast cancer, including bilateral oophorectomy, ovarian
suppression, and endocrine therapy.7,8 More speciﬁcally, theY-NC-ND license.selective ER modulator tamoxifen has improved survival both in
early breast cancer and in metastatic disease. Tamoxifen has also
decreased the incidence of breast cancer in at-risk patients and in
women with ductal carcinoma in situ.6,9 More recent therapeutic
options include agents that either decrease estrogen production
such as aromatase inhibitors10 or degrade the receptor itself (i.e.,
fulvestrant).11 These agents inhibit ER signaling as effectively as or
more effectively than tamoxifen and have proved clinically suc-
cessful.12 As a result, these therapeutic options have improved
breast cancer outcomes in the metastatic setting, thereby delaying
the need for chemotherapy.Endocrine therapy resistance
Despite the beneﬁts of endocrine therapy, many ER/PR-
expressing tumors do not respond to endocrine manipulation (de
novo [or primary] resistance), and in some cases initially responsive
tumors eventually progress (acquired [or secondary] resistance).
Acquired resistance may occur while receiving therapy but also
following completion of adjuvant endocrine therapy. Recent ad-
vances in the understanding of ER biology revealed an increasingly
complex process of ER signaling and interaction with other growth
factor signaling pathways in the cancer cell.13 The mechanisms
contributing to resistance to endocrine therapy are inherently
complex. Following prolonged periods of endocrine therapy,
resistance has been implicated through various growth factors and
Fig. 1. Signaling pathways involved in interaction with mTOR. Akt, protein kinase B;
4E-BP1, 4E-binding protein 1; ErbB, epidermal growth factor; eIF-4E, eukaryotic
initiation factor 4E; S6 ¼ ribosomal protein S6; IGF-1, insulin-like growth factor-1;
mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase; PTEN,
phosphatase and tensin homolog deleted from chromosome 10; S6K1, S6 kinase 1; TSC,
tuberous sclerosis complex; VEGF, vascular endothelial growth factor.
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(IGFR), HER2, mitogen-activated protein kinases (MAPK), Src,
epidermal growth factor receptor (EGFR), and mammalian target of
rapamycin (mTOR).14,15 The recognition of this molecular cross-talk
between ER and other growth factor signaling pathways improves
our understanding of the causes of endocrine resistance and
identiﬁes the potential for development of new therapeutic stra-
tegies to overcome endocrine resistance in breast cancer. These
recent advances in understanding the complex interaction of ER
signaling with other growth factor signaling pathways suggest that
targeting the ER as an isolated pathway may not be an optimal
therapeutic strategy. Rather, simultaneous inhibition of other active
signaling elements that interact with ER may be necessary to
improve endocrine response and prevent resistance. Exploring new
targeted therapies in combination with classic endocrine modal-
ities represents a new strategy in overcoming endocrine therapy
resistance. Various inhibitors have been investigated for these
targets, including agents directed at tyrosine kinase moieties, an-
tibodies against surface growth factor receptors, or other drugs that
target key signal transduction mediators of growth factor signaling,
such as farnesyl transferase inhibitors and mTOR inhibitors.16 To
date, mTOR inhibitors appear to be the most promising.
Endocrine resistance: targeting mTOR
mTOR is a serine/threonine protein kinase that regulates cell
growth, proliferation, motility, cell survival and apoptosis, protein
synthesis, and metabolism (Fig. 1).17,18 mTOR belongs to the phos-
phatidylinositol 3-kinase (PI3K)-related kinase protein family and
integrates signaling from upstream pathways, including insulin,
growth factors (such as IGF-1), and amino acids.17 The protein exists
as two distinct complexes: mTOR complex 1 (mTORC1) and mTOR
complex 2 (mTORC2).19
mTOR is a downstream mediator in the PI3K/Akt-signaling
pathway and is critical for cell survival.20 Rapamycin and rapamy-
cin analogs are speciﬁc mTOR antagonists that target this pathway
and block the downstream signaling elements, resulting in cell
cycle arrest in the G1 phase.21 In breast cancer, the PI3K/Akt
pathway can be activated via the HER (or ErbB) family of growth
factor receptors, the IGFR, and the ER.22 This pathway has been
demonstrated to play a central role in the development of resis-
tance to trastuzumab and tamoxifen therapy.23e25 Therefore, tar-
geting the PI3K/Akt pathway with mTOR antagonists may increase
their therapeutic efﬁcacy.
Upstream regulators of the PI3K/Akt pathway include the tumor
suppressor gene phosphatase and tensin homolog deleted from
chromosome 10 (PTEN). PTEN inhibits the activity of PI3K, and the
hyperactivation of PI3K/Akt signaling elements in PTEN-deﬁcient
malignancies suggests that these cancers are dependent on this
pathway for growth and maintenance.26 In fact, loss of PTEN sup-
pressor gene function has been associated with Akt activation20
and development of resistance to trastuzumab.24
Tumor cell lines lacking PTEN exhibited high sensitivity to the
mTOR inhibitor temsirolimus.27 Most breast cancer cell lines highly
sensitive to temsirolimus were found to be estrogen dependent, to
overexpress Erb-2, and/or to have PTEN deletions. Breast cancer cell
lines resistant to temsirolimus treatment lacked these features.
Breast cancer cell lines sensitive to the inhibitory effects of tem-
sirolimus generally had higher levels of activated Akt, perhaps
leading to downstream activation of mTOR and subsequent sensi-
tivity to mTOR inhibitors.28 Alternately, a mechanistic study of
everolimus has shown PIK3CA mutations are selectively sensitive
tomTOR inhibitionwhile tumor cells with PTEN loss of function are
not susceptible to pharmacological inhibition, suggesting activation
of these two pathways have functionally distinct consequences.29Recently, both control MCF-7 cells and MCF-7/Aro (aromatase-
expressing) cells were found to be susceptible to treatment with
the rapamycin analog everolimus in vitro. Everolimus was found to
almost completely inhibit estradiol-induced proliferation in control
MCF-7 cells and estradiol and androstenedione-induced prolifera-
tion in MCF-7/Aro cells, suggesting that mTOR signaling is required
for estrogen-regulated proliferative response in MCF-7 cells. Also,
combination therapy with letrozole and everolimus resulted in
increased inhibition of cell proliferation, and the two therapies
demonstrated a synergistic effect.30
Evidence supporting the rationale for everolimus use in HR-positive
breast cancer
Preclinical studies have shown that breast cancer cells with up-
regulated Akt signaling are resistant to hormonal therapy, but
responsiveness to endocrine treatment may be restored by ever-
olimus or other mTOR inhibitors.31,32 In models of ER-positive
breast cancer, small concentrations of everolimus reduced cell
growth in vitro and increased antitumor activity of letrozole.33
An initial evaluation of temsirolimus with letrozole suggested
the potential utility of mTOR inhibitors in combination with
endocrine therapies as an effective treatment option in HR-positive
breast cancer.22,34 A phase III study of temsirolimus in combination
with letrozole was subsequently conducted in patients with HR-
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were previously treated with chemotherapy or hormonal therapy.
However, the study showed no beneﬁt of the temsirolimus/letro-
zole combination over letrozole alone in progression-free survival
(PFS) (8.9 vs 9.0 months; hazard ratio ¼ 0.90; 95% conﬁdence in-
terval [CI]; 0.76e1.07; P ¼ 0.250).35 Conversely, early-phase clinical
trials suggested that everolimus may be a viable treatment option
for HR-positive breast cancer. A phase I dose-escalating study of
everolimus plus letrozole in postmenopausal women or men with
stable metastatic breast cancer or progression after 4 months of
ﬁrst- or second-line therapy with letrozole alone (n ¼ 18) found
that one patient had a complete response lasting >22 months and
another experienced a 28% reduction in liver metastases.36 Subse-
quent clinical trials addressed the beneﬁts of everolimus in com-
bination with endocrine therapy (Table 1).37e42 A phase II,
randomized study of neoadjuvant everolimus plus letrozole versus
placebo plus letrozole in patients with ER-positive breast cancerTable 1
Clinical trials of everolimus in HR-positive advanced breast cancer.
Study Study design Patients (n) Treatments
Baselga
et al., 2012a,37
Placebo-controlled,
randomized phase III
Postmenopausal
ERþ advanced
BC (n ¼ 724)
Exemestane (
þ everolimus
BOLERO-2 Exemestane (
þ placebo
Hortobagyi
et al., 2011a,38
Placebo-controlled,
randomized phase III
Postmenopausal
ERþ advanced
BC (n ¼ 724)
Exemestane (
þ everolimus
BOLERO-2
(12-month
data update)
Exemestane (
þ placebo
Piccart et al.,
2012a,39
Placebo-controlled,
randomized phase III
Postmenopausal
ERþ advanced
BC (n ¼ 724)
Exemestane (
þ everolimus
BOLERO-2
(18-month
data update)
Exemestane (
þ placebo
Bachelot et al.,
201240
Randomized phase II,
Simon 2-stage
HRþ, HER2 MBC Tamoxifen (2
þ everolimus
(n ¼ 54)
TAMRAD Tamoxifen (2
(n ¼ 57)
Baselga et al.,
200941
Phase II randomized Postmenopausal
women with
operable ERþ BC
(n ¼ 270)
Everolimus (1
þ neoadjuvan
(2.5 mg/day)
Neoadjuvant
(2.5 mg/day)
(n ¼ 132)
Badin et al.,
201042
Phase II open-label ERþ MBC with AI
therapy failure
within 6 months
(n ¼ 11)
Everolimus (1
þ fulvestrant
250 mg day 1
28, and mont
AI, aromatase inhibitor; BC¼ breast cancer; CBR¼ clinical beneﬁt rate (CRþ PRþ SD at 6m
positive; HER2, human epidural growth factor 2 receptorenegative; HRþ, hormone re
PR ¼ partial response; pts ¼ patients; SD ¼ stable disease; TTP ¼ time to progression.
a Data based on local review.
b By palpation.showed higher response rates in the everolimus arm compared
with placebo (68.1% vs 59.1%, respectively; P ¼ 0.062). Notable re-
ductions in progesterone receptor and cyclin D1 expression were
documented in both arms, whereas down-regulation of phos-
phorylated S6 protein occurred only in the everolimus arm. Sig-
niﬁcant reduction in Ki67 expression, a biomarker of cell
proliferation, occurred in 57% of patients in the everolimus arm
versus 30% of patients in the placebo arm (P < 0.01). Therefore,
everolimus increased the efﬁcacy of letrozole in the treatment of
ER-positive breast cancer in a neoadjuvant setting in terms of both
clinical response and antiproliferative effect.41 Additionally, an
ongoing phase II study of everolimus in combination with fulves-
trant in patients (n ¼ 11) with HR-positive metastatic breast cancer
with aromatase inhibitor therapy failure within 6 months found
that at the time of data presentation the median time to progres-
sion (TTP) was 8.6 months and the clinical beneﬁt rate (CBR) was
55%.42Objective response
rates/clinical beneﬁt rate
Disease progression
25 mg/day)
(10 mg/day)
ORR ¼ 9.5%
SD ¼ 70.1%
PFS ¼ 6.9 months
25 mg/day) ORR ¼ 0.4%
(P < 0.001, vs placebo
þ exemestane)
SD ¼ 58.6%
PFS ¼ 2.8 months
(hazard ratio ¼ 0.43;
95% CI: 0.35e0.54; P < 0.001)
25 mg/day)
(10 mg/day)
ORR ¼ 12.0%
CBR ¼ 50.5%
PFS ¼ 7.4 months
25 mg/day) ORR ¼ 1.3%
(P < 0.001, vs placebo
þ exemestane)
CBR ¼ 25.5%
(P < 0.001, vs placebo
þ exemestane)
PFS ¼ 3.2 months
(hazard ratio ¼ 0.44;
95% CI: 0.36e0.53; P < 0.001)
25 mg/day)
(10 mg/day)
ORR ¼ 12.6%
CBR ¼ 51.3%
PFS ¼ 7.8 months
25 mg/day) ORR ¼ 1.7%
(P < 0.001, vs placebo
þ exemestane)
CBR ¼ 26.4%
(P < 0.001, vs placebo
þ exemestane)
PFS ¼ 3.2 months
(hazard ratio ¼ 0.45;
95% CI: 0.38e0.54; P < 0.001)
0 mg/day)
(10 mg/day)
CBR ¼ 61% TTP ¼ 8.6 months
0 mg/day) CBR ¼ 42%
(exploratory P ¼ 0.045
vs tamoxifen alone)
TTP ¼ 4.5 months
(exploratory P ¼ 0.002)
0 mg/day)
t letrozole
(n ¼ 138)
ORRb ¼ 68.1%
(95% CI: 60.3e75.9)
Not evaluated
letrozole
þ placebo
ORRb ¼ 59.1%
(95% CI: 50.7e67.5;
P ¼ 0.062, vs letrozole
þ placebo)
Not evaluated
0 mg/day)
(500 mg day 1,
4, 250 mg day
hly thereafter)
CBR ¼ 55% TTP ¼ 8.6 months
onths); CI¼ conﬁdence interval; CR¼ complete response; ERþ, estrogen receptore
ceptorepositive; MBC ¼ metastatic breast cancer; ORR ¼ objective response rate;
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A GINECO (Groupe d’Investigateurs Nationaux pour l’Etude des
Cancers de l’Ovaire et du Sein) randomized, phase II trial evaluated
everolimus in combination with tamoxifen versus tamoxifen alone
in patients with HR-positive, HER2-negative metastatic breast
cancer with previous exposure to aromatase inhibitors (TAMRAD).
Patients were randomly assigned according to primary or second-
ary hormone resistance. Primary resistance was deﬁned as relaps-
ing during or within 6 months of stopping adjuvant AI treatment or
progressing within 6 months of starting AI treatment in the met-
astatic setting. Secondary resistance was deﬁned as relapsing >6
months after stopping adjuvant AI treatment or responding for 6
months to AI treatment in the metastatic setting. Overall, the CBR
was 42% with tamoxifen alone versus 61% with tamoxifen plus
everolimus at median 13 months of follow-up. Median TTP was 4.5
months with tamoxifen alone versus 8.6 months with tamoxifen
plus everolimus. Therefore, tamoxifen plus everolimus demon-
strated signiﬁcant improvement in CBR at 6months compared with
tamoxifen alone. In an exploratory analysis of primary and sec-
ondary hormone-resistant subgroups, everolimus combination
therapy resulted in a median TTP of 5.4 months for patients with
primary resistance compared with 14.8 months for those with
acquired resistance. Similarly, CBR was greatest among patients
receiving combination therapy with secondary resistance (74%
compared with 48% for monotherapy), while patients with primary
hormone resistance had only a slightly higher CBR with the addi-
tion of everolimus (46% compared with 36% for monotherapy).40
BOLERO-2 study
The promising results observed in phase II studies warranted
further studies in patients with ER-positive, HER2-negative meta-
static breast cancer and previous exposure to aromatase inhibitors.
BOLERO-2 was a multinational, double-blind, placebo-controlled
phase III study of postmenopausal women with ER-positive, HER2-Table 2
PI3K/mTOR inhibitors being investigated for treatment of HR-positive advanced breast c
Agents Phase Patient population
mTOR inhibitors
Ridaforolimus II ERþ, HER2 advanced BC
II ERþ, HER2 advanced BC
AZD2014 I ERþ advanced BC
PI3K inhibitors
XL147 I/II ERþ, HER2 BC refractory
to nonsteroidal AI
BKM120 III ERþ, HER2 BC refractory
to nonsteroidal AI
I HRþ advanced BC
I ERþ stage IV BC
GDC-0941 II HRþ advanced BC resistant
to AI
Dual PI3K/mTOR inhibitors
XL765 I/II ERþ, HER2 BC refractory
to nonsteroidal AI
BEZ235 I HRþ advanced BC
PF-04691502 II ERþ, HER2 early BC
GDC-0980 II HRþ advanced BC to AI
AI, aromatase inhibitor; BC, breast cancer; ERþ, estrogen receptorepositive; HER2, humnegative locally advanced or metastatic breast cancer refractory to
nonsteroidal aromatase inhibitors who had documented recur-
rence or progression. Individuals were stratiﬁed by sensitivity to
previous hormonal therapy and the presence of visceral metastasis.
Patients were then randomly assigned (2:1) to receive everolimus
10 mg daily or placebo orally once daily, with both arms receiving
exemestane 25 mg daily. Treatment was continued until disease
progression or unacceptable toxicity occurred. The primary
outcome was PFS as assessed by the investigators. Secondary out-
comes included overall survival, overall response rate, time to
deterioration of Eastern Cooperative Oncology Group performance
status, safety, and change in quality-of-life scores over time. Be-
tween June 2009 and January 2011, 724 patients were randomly
assigned from 24 countries; 84% had hormone-sensitive disease
and 56% had visceral disease.
A planned interim analysis of 359 PFS events determined that
everolimus plus exemestane signiﬁcantly improved PFS compared
with exemestane alone (6.9 vs 2.8 months, respectively; hazard
ratio ¼ 0.43; 95% CI: 0.35e0.54, P < 0.001 [local assessment]).37
Objective response rates were 9.5% with everolimus plus exemes-
tane and 0.4% with exemestane alone (P < 0.001), and the per-
centages of patients with stable disease were 70.1% and 58.6%,
respectively. A prespeciﬁed 12-month follow-up analysis deter-
mined that median PFS was 7.4 months versus 3.2 months (hazard
ratio ¼ 0.44; 95% CI: 0.36e0.53, P < 0.001 [local assessment]) and
objective response rates were 12.0% and 1.3% for combination
versus exemestane-only therapy, respectively (P < 0.001).38 The
clinical beneﬁt rates for the combination versus exemestane-only
therapy groups were 50.5% and 25.5%, respectively (P < 0.001).
PFS rates were similar regardless of whether or not everolimus dose
intensity during the studywas reduced, possibly because of adverse
events (<7.5 mg/day, hazard ratio ¼ 0.40, 95% CI: 0.31e0.52;
7.5 mg/day, hazard ratio ¼ 0.45, 95% CI: 0.37e0.56).43 Recently,
an 18-month follow-up analysis determined that the median PFS
was 7.8 months versus 3.2 months (hazard ratio ¼ 0.45; 95% CI:
0.38e0.54, P < 0.001 [local assessment]) and objective responseancer.
Treatment Clinicaltrials.gov
Ridaforolimus þ dalotuzumab vs
exemestane vs ridaforolimus or
dalotuzumab monotherapy
NCT01234857
Ridaforolimus þ dalotuzumab vs
exemestane vs ridaforolimus þ
exemestane
NCT01605396
AZK2014 þ fulvestrant NCT01597388
XL147 þ letrozole NCT01082068
BKM120 þ fulvestrant vs placebo
þ fulvestrant
NCT01610284
BKM120 þ letrozole
Intermittent BKM120 þ letrozole
NCT01248494
BKM120 þ fulvestrant NCT01339442
GDC-0941 þ fulvestrant vs placebo
þ fulvestrant
NCT01437566
XL765 þ letrozole NCT01082068
BEZ235 þ letrozole NCT01248494
PF-04691502 vs PF-04691502 þ
letrozole vs letrozole
NCT01430585
GDC-0980 þ fulvestrant vs placebo
þ fulvestrant
NCT01437566
an epidural growth factor 2 receptorenegative; HRþ, hormone receptorepositive.
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therapy, respectively (P < 0.001).39 The clinical beneﬁt rates for the
combination versus exemestane-only therapy groups were 51.3%
and 26.4%, respectively (P < 0.001).
Clinical considerations and future direction
While results from TAMRAD and BOLERO-2 demonstrated
everolimus in combination with endocrine therapy to derive sig-
niﬁcant clinical beneﬁt compared with endocrine monotherapy, no
such beneﬁt was observed with the combination of temsirolimus
and letrozole in patients with breast cancer refractory to previous
endocrine treatment. Although the exact causes of the differences
in efﬁcacy cannot be deﬁnitively determined, some potential causes
may be due to stratiﬁcation with respect to previous endocrine
responsiveness and differences in dosing schedules. In the ever-
olimus studies, patients unresponsive to previous endocrine ther-
apy were included, whereas in the temsirolimus study, patients
could have been either treated or not treated previously with
endocrine therapy. Also, patients in the everolimus study were
administered 10mg daily throughout the trial, whereas those in the
temsirolimus study were administered the drug for 5 days every 2
weeks, suggesting that continuous dosing may be necessary for
effective mTOR inhibition.
Currently, new therapies that target the PI3K/mTOR pathway in
HR-positive advanced breast cancer (Table 2) are being developed.
The mTOR inhibitors ridaforolimus and AZD2014 are being evalu-
ated in phase II clinical trials of ER-positive, HER2-negative
advanced breast cancer. Drugs that selectively inhibit PI3K alone
(XL147, BKM120, and GDC-0941) or both PI3K and mTOR (XL765,
BEZ235, PF-04691502, GDC-0980) are also in development.
Although the majority of these studies are in phase I and II devel-
opment, BKM120 is currently in a phase III study in combination
with fulvestrant in ER-positive, HER2-negative breast cancer re-
fractory to nonsteroidal aromatase inhibitors.
Conclusion
mTOR signaling pathway activation plays a central role in the
development of hormone therapy resistance in breast cancer. Use
of mTOR inhibitors, including everolimus, has been shown to in-
crease efﬁcacy of aromatase inhibitors and signiﬁcantly improve
PFS in patients with HR-positive metastatic breast cancer. Ongoing
and future studies are focusing on assessing the beneﬁt of
combining everolimus with other endocrine agents and the
development of other inhibitors of the PI3K/mTOR pathway for
treating HR-positive advanced breast cancer. Considering the
multiple pathways involved in the HR network, targeting other
components of pathologically activated intracellular signaling in
breast cancer may prove to be a new direction in clinical research.
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